European VC Sofinnova Partners raises $540M late-stage crossover healthcare fund badams Wed, 03/03/2021 - 04:10.: Sofinnova Partners has pulled in a healthy €445 million ($540 million) in its latest capital raise as the European venture capital firm seeks out late-stage plays in biotech and medtech. The fund was “oversubscribed and significantly exceeded its target,” the Paris-based firm said, and with this latest cash boost it's set to continue its focus on European clinical-stage companies “needing scale-up capital” while also supporting “best-in-class companies” in the U.S. and elsewhere. It did, not however, detail any particular targets it was going after.